Targeted nanozyme-enabled treatment of cardiovascular diseases

Abstract

Cardiovascular diseases (CVDs) pose a significant threat to human health due to the high mortality and morbidity rates. Traditional drugs often have limited efficacy due to inherent constraints, such as low bioavailability and notable side effects. As a highly regarded therapeutic strategy, nanotechnology offers new perspectives and means for treating CVDs. Nanozyme-based targeted therapeutic drugs specifically address the biological processes in areas affected by CVDs, thereby achieving precise treatment. Compared to traditional drugs, targeted nanozymes offer advantages, such as high efficiency, specificity, controllability, and fewer side effects, showing great efficacy in treating CVDs. This paper first explores the design strategies and mechanisms of nanozyme-based targeted therapy, then introduces its application in key CVDs, such as ischemic stroke, myocardial infarction, and coronary heart disease. Finally, the paper discusses the challenges of introducing targeted nanozymes into clinical applications and the future development prospects in the treatment of CVDs.

Keywords

active targeting / nanozymes / cardiovascular diseases

References

[1] Abdul Ghani MA, Ugusman A, Latip J, Zainalabidin S: Role of Terpenophenolics in Modulating Inflammation and Apoptosis in Cardiovascular Diseases: A Review. International Journal of Molecular Sciences 2023, 24: 5339.

[2] Ventura HO, Elagizi A, Lavie CJ: Optimal Prevention of Cardiovascular Diseases: The Earlier the Better. Journal of the American College of Cardiology 2023, 81: 1162-1164.

[3] Cai S, Zhao M, Zhou B, Yoshii A, Bugg D, Villet O, et al.: Mitochondrial Dysfunction in Macrophages Promotes Inflammation and Suppresses Repair After Myocardial Infarction. Journal of Clinical Investigation 2023, 133: e159498.

[4] Guida G, Attanasio A, Disabato G, Paglione G, Piepoli M: Editorial Comments: Focus on Cardiovascular Diseases. European Journal of Preventive Cardiology 2024, 31: 501-503.

[5] Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, Weber C: Immunotherapy for Cardiovascular Disease. European Heart Journal 2019, 40: 3937-3946.

[6] Singh S: Antioxidant Nanozymes as Next-Generation Therapeutics to Free Radical-Mediated Inflammatory Diseases: A Comprehensive Review. International Journal of Biological Macromolecules 2024, 260(Pt 1): 129374.

[7] Zhao J, Guo F, Hou L, Zhao Y, Sun P: Electron Transfer-Based Antioxidant Nanozymes: Emerging Therapeutics for Inflammatory Diseases. Journal of Controlled Release 2023, 355: 273-291.

[8] Ren X, Chen D, Wang Y, Li H, Zhang Y, Chen H, et al.: Nanozymes-Recent Development and Biomedical Applications. Journal of Nanobiotechnology 2022, 20: 92.

[9] Zhang Y, Liu W, Wang X, Liu Y, Wei H: Nanozyme-Enabled Treatment of Cardio- and Cerebrovascular Diseases. Small 2023, 19: e2204809.

[10] Sheng J, Wu Y, Ding H, Feng K, Shen Y, Zhang Y, et al.: Multienzyme-Like Nanozymes: Regulation, Rational Design, and Application. Advanced Materials 2024, 36: e2211210.

[11] Gong Y, Liu H, Ke S, Zhuo L, Wang H: Latest Advances in Biomimetic Nanomaterials for Diagnosis and Treatment of Cardiovascular Disease. Frontiers in Cardiovascular Medicine 2022, 9: 1037741.

[12] Liu X, Chen B, Chen J, Wang X, Dai X, Li Y, et al.: A Cardiac-Targeted Nanozyme Interrupts the Inflammation-Free Radical Cycle in Myocardial Infarction. Advanced Materials 2024, 36: e2308477.

[13] Liao J, Li Y, Fan L, Sun Y, Gu Z, Xu QQ, et al.: Bioactive Ceria Nanoenzymes Target Mitochondria in Reperfusion Injury to Treat Ischemic Stroke. ACS Nano 2024, 18.

[14] Zhong Y, Yang Y, Xu Y, Qian B, Huang S, Long Q, et al.: Design of a Zn-Based Nanozyme Injectable Multifunctional Hydrogel with ROS Scavenging Activity for Myocardial Infarction Therapy. Acta Biomaterialia 2024, 177: 62-76.

[15] Xiang K, Wu H, Liu Y, Wang S, Li X, Yang B, et al.: MOF-Derived Bimetallic Nanozyme to Catalyze ROS Scavenging for Protection of Myocardial Injury. Theranostics 2023, 13: 2721-2733.

[16] Ye T, Chen C, Wang D, Huang C, Yan Z, Chen Y, et al.: Protective Effects of Pt-N-C Single-Atom Nanozymes against Myocardial Ischemia-Reperfusion Injury. Nature Communications 2024, 15: 1682.

[17] Liu J, Sun J, Song Y, Wang M, Zhao P, Wang W, et al.: Prussian Blue Nanozyme Treatment of Ischemic Brain Injury via Reducing Oxidative Stress Inhibits Inflammation, Suppresses Apoptosis, and Promotes Neurological Recovery. ACS Chemical Neuroscience 2023. [Epub ahead of print]

[18] Jiang Z, Wang W, Zhao Y, Li T, Xin D, Gai C, et al.: Mitochondria-Targeted Cerium Vanadate Nanozyme Suppressed Hypoxia-Ischemia Injury in Neonatal Mice via Intranasal Administration. Journal of Controlled Release 2024, 365: 1074-1088.

[19] Liu X, Geng X, Shi Y, Liang J, Zhao L: Biomimetic Oxygen-Boosted Hybrid Membrane Nanovesicles as the Treatment Strategy for Ischemic Stroke with the Concept of the Neurovascular Unit. Biomaterials Advances 2023, 148: 213379.

[20] Sun Y, Xu T, Qian Y, Chen Q, Xiong F, Du W, et al.: NOS-Like Activity of CeO₂ Nanozymes Contributes to Diminishing the Vascular Plaques . Journal of Nanobiotechnology 2024, 22: 12.

[21] Wang Z, Yang N, Hou Y, Li Y, Yin C, Yang E, et al.: L-Arginine-Loaded Gold Nanocages Ameliorate Myocardial Ischemia/Reperfusion Injury by Promoting Nitric Oxide Production and Maintaining Mitochondrial Function. Advanced Science 2023, 10: e2302123.

[22] Zhang W, Sun M, Liu Y, Zhang Y, Xu L, Luo Y, et al.: Platelet Membrane-Functionalized Hollow Mesoporous Prussian Blue Nanomedicine for Comprehensive Thrombolytic Management by Targeted Enhanced Fibrinolysis and ROS Scavenging. Chemical Engineering Journal 2023, 474: 145515.

[23] Jheng PR, Chiang CC, Kang JH, Fan YJ, Wu KC, Chen YT, et al.: Cold Atmospheric Plasma-Enabled Platelet Vesicle Incorporated Iron Oxide Nano-Propellers for Thrombolysis. Materials Today Bio 2023, 23: 100876.

[24] Matsumori A: Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases. Global Heart 2022, 17: 80.

[25] Villalba-Rodríguez AM, Martínez-Zamudio LY, Martínez SAH, Rodríguez-Hernández JA, Melchor-Martínez EM, Flores-Contreras EA, et al.: Nanomaterial Constructs for Catalytic Applications in Biomedicine: Nanobiocatalysts and Nanozymes. Topics in Catalysis 2023, 66: 707-722.

[26] Li Q, Liu Y, Dai X, Jiang W, Zhao H: Nanozymes Regulate Redox Homeostasis in ROS-Related Inflammation. Frontiers in Chemistry 2021, 9: 740607.

[27] Liang S, Tian X, Wang C: Nanozymes in the Treatment of Diseases Caused by Excessive Reactive Oxygen Specie. Journal of Inflammation Research 2022, 15: 6307-6328.

[28] Singh N, Sherin GR, Mugesh G: Antioxidant and Prooxidant Nanozymes: From Cellular Redox Regulation to Next-Generation Therapeutics. Angewandte Chemie International Edition 2023, 62: e202301232.

[29] Ulaganathan T, Perales S, Mani S, Baskhairoun BA, Rajasingh J: Pathological Implications of Cellular Stress in Cardiovascular Diseases. The International Journal of Biochemistry & Cell Biology 2023, 158: 106397.

[30] Liang Y, Ruan W, Jiang Y, Smalling R, Yuan X, Eltzschig HK: Interplay of Hypoxia-Inducible Factors and Oxygen Therapy in Cardiovascular Medicine. Nature Reviews Cardiology 2023, 20: 723-737.

[31] Andrabi SM, Sharma NS, Karan A, Shahriar SMS, Cordon B, Ma B, et al.: Nitric Oxide: Physiological Functions, Delivery, and Biomedical Applications. Advanced Science 2023, 10: e2303259.

[32] Zhao Y, Xiong W, Li C, Zhao R, Lu H, Song S, et al.: Hypoxia-Induced Signaling in the Cardiovascular System: Pathogenesis and Therapeutic Targets. Signal Transduction and Targeted Therapy 2023, 8: 431.

[33] Li J, Zhang J, Yu P, Xu H, Wang M, Chen Z, et al.: ROS-Responsive & Scavenging NO Nanomedicine for Vascular Diseases Treatment by Inhibiting Endoplasmic Reticulum Stress and Improving NO Bioavailability. Bioactive Materials 2024, 37: 239-252.

[34] Byrnes JR, Wolberg AS: New Findings on Venous Thrombogenesis. Hamostaseologie 2017, 37: 25-35.

[35] Zia A, Wu Y, Nguyen T, Wang X, Peter K, Ta HT: The Choice of Targets and Ligands for Site-Specific Delivery of Nanomedicine to Atherosclerosis. Cardiovascular Research 2020, 116: 2055-2068.

[36] Feng L, Dou C, Xia Y, Li B, Zhao M, Yu P, et al.: Neutrophil-like Cell-Membrane-Coated Nanozyme Therapy for Ischemic Brain Damage and Long-Term Neurological Functional Recovery. ACS Nano 2021, 15: 2263-2280.

[37] Hu R, Dai C, Dong C, Ding L, Huang H, Chen Y, et al.: Living Macrophage-Delivered Tetrapod PdH Nanoenzyme for Targeted Atherosclerosis Management by ROS Scavenging, Hydrogen Anti-inflammation, and Autophagy Activation. ACS Nano 2022, 16: 15959-15976.

[38] Tang G, He J, Liu J, Yan X, Fan K: Nanozyme for Tumor Therapy: Surface Modification Matters. Exploration 2021, 1: 75-89.

[39] He H, Han Q, Wang S, Long M, Zhang M, Li Y, et al.: Design of a Multifunctional Nanozyme for Resolving the Proinflammatory Plaque Microenvironment and Attenuating Atherosclerosis. ACS Nano 2023, 17: 14555-14571.

[40] Zhao Q, Du W, Zhou L, Wu J, Zhang X, Wei X, et al.: Transferrin-Enabled Blood-Brain Barrier Crossing Manganese-Based Nanozyme for Rebalancing the Reactive Oxygen Species Level in Ischemic Stroke. Pharmaceutics 2022, 14: 1122.

[41] Wang L, Qiu S, Li X, Zhang Y, Huo M, Shi J: Myocardial-Targeting Tannic Cerium Nanocatalyst Attenuates Ischemia/Reperfusion Injury. Angewandte Chemie International Edition 2023, 62: e202305576.

[42] Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W: Macrophage-Targeted Nanomedicine for the Diagnosis and Treatment of Atherosclerosis. Nature Reviews Cardiology 2022, 19: 228-249.

[43] Hu D, Li R, Li Y, Wang M, Wang L, Wang S, et al.: Inflammation-Targeted Nanomedicines Alleviate Oxidative Stress and Reprogram Macrophages Polarization for Myocardial Infarction Treatment. Advanced Science 2024, 11: e2308910.

[44] Han Q, Wang C, Liu J, Wang C, Zhang H, Ni Q, et al.: Application of Nanozymes and its Progress in the Treatment of Ischemic Stroke. Translational Stroke Research 2024, 15: 880-892.

[45] Wang Z, Zhao Y, Hou Y, Tang G, Zhang R, Yang Y, et al.: A Thrombin-Activated Peptide-Templated Nanozyme for Remedying Ischemic Stroke via Thrombolytic and Neuroprotective Actions. Advanced Materials 2024, 36: e2210144.

[46] Wojtasin´ska A, Fra˛k W, Lisin´ska W, Sapeda N, Młynarska E, Rysz J, et al.: Novel Insights into the Molecular Mechanisms of Atherosclerosis. International Journal of Molecular Sciences 2023, 24: 13434.

[47] Fu X, Yu X, Jiang J, Yang J, Chen L, Yang Z, et al.: Small Molecule-Assisted Assembly of Multifunctional Ceria Nanozymes for Synergistic Treatment of Atherosclerosis. Nature Communications 2022, 13: 6528.

[48] Yang Q, Jiang H, Wang Y, Leng X, Wang Y, Tong J, et al.: Plaque Macrophage-Targeting Nanosystems with Cooperative Co-Regulation of ROS and TRAF6 for Stabilization of Atherosclerotic Plaques. Advanced Functional Materials 2023, 33: 2301053.

[49] Zhang J, Guo Y, Bai Y, Wei Y: Application of Biomedical Materials in the Diagnosis and Treatment of Myocardial Infarction. Journal of Nanobiotechnology 2023, 21: 298.

[50] Fang J, Wang Z, Miao CY: Angiogenesis After Ischemic Stroke. Acta Pharmacologica Sinica 2023, 44: 1305-1321.

[51] Song J, Yang G, Song Y, Jiang Z, Jiang Y, Luan Y, et al.: Neutrophil Hitchhiking Biomimetic Nanozymes Prime Neuroprotective Effects of Ischemic Stroke in a Tailored “Burning the Bridges” Manner. Advanced Functional Materials 2024, 34: 2315275.

[52] Wang S, Zhang J, Li W, Chen D, Tu J, Sun C, et al.: Hyaluronic Acid-Guided Assembly of Ceria Nanozymes as Plaque-Targeting ROS Scavengers for Anti-Atherosclerotic Therapy. Carbohydrate Polymers 2022, 296: 119940.

[53] Chen S, Luo X, Sun Y, Jin W, He R: A Novel Metabolic Reprogramming Strategy for the Treatment of Targeting to Heart Injury-Mediated Macrophages. International Immunopharmacology 2023, 122: 110377.